<DOC>
	<DOC>NCT01498887</DOC>
	<brief_summary>This study will assess the efficacy of fingolimod in patients with short duration relapsing-remitting multiple sclerosis who have not been previously treated with disease-modifying therapies (DMTs), versus patients with the same disease duration who have previously received first-line Disease Modifying Therapies.</brief_summary>
	<brief_title>Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients diagnosed with multiple sclerosis, according to the 2010 revised McDonald criteria, with a relapsingremitting course, and with at least 9 T2 lesions consistent with the disease, with disease duration greater than or equal to one year and less than or equal to five years. Patients who have had at least two relapses in the past two years and an Expanded Disability Status Scale score between 0 and 3.5, inclusive. Patients Treatment na√Øve: patients who have never been treated with a Disease Modifying Therapy or Previously treated with a firstline Disease Modifying Therapy Patients who have received treatment with: Fingolimod at any time (e.g. participation in a fingolimod clinical trial), Immunosuppressant drugs such as azathioprine or methotrexate at any time; Immunoglobulins in the past 6 months. Monoclonal antibodies including natalizumab, Cladribine, cyclophosphamide or mitoxantrone, at any time. Other protocol defined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>Fingolimod</keyword>
	<keyword>Early multiple sclerosis</keyword>
	<keyword>Naive patients</keyword>
</DOC>